MXCT
MAXCYTE, INC.
NASDAQ · Healthcare · Medical - Devices · US
$1.30
+0.00%Year over year
Reported trailing growth
- Revenue
- -13.2%
- EBITDA
- +30.6%
- EBIT
- +35.2%
- EPS
- +22.3%
- Free cash flow
- +37.8%
- Operating cash flow
- +37.0%
Forward estimates
Based on analyst estimates
- Revenue
- +9.8%
- EBITDA
- +14.4%
- EPS
- +12.8%
Three-year CAGR
- Revenue
- -9.3%
- EBITDA
- -7.5%
- EBIT
- +11.5%
- Net income
- -8.7%
- EPS
- -7.7%
- Free cash flow
- -23.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026